TCIM
VYGR icon

TIAA CREF Investment Management’s Voyager Therapeutics VYGR Stock Holding History

TIAA CREF Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.57M Buy
81,968
+24,543
+43% +$320K ﹤0.01% 2118
2018
Q4 		$540K Sell
57,425
-20,037
-26% -$257K ﹤0.01% 2530
2018
Q3 		$1.47M Sell
77,462
-3,723
-5% -$71.4K ﹤0.01% 2271
2018
Q2 		$1.59M Buy
81,185
+44,703
+123% +$884K ﹤0.01% 2291
2018
Q1 		$685K Hold
36,482
– – ﹤0.01% 2613
2017
Q4 		$606K Sell
36,482
-813
-2% -$13.9K ﹤0.01% 2688
2017
Q3 		$768K Hold
37,295
– – ﹤0.01% 2643
2017
Q2 		$334K Buy
37,295
+3,939
+12% +$39.6K ﹤0.01% 3015
2017
Q1 		$442K Sell
33,356
-4,622
-12% -$56.1K ﹤0.01% 2832
2016
Q4 		$484K Sell
37,978
-958
-2% -$12.3K ﹤0.01% 2865
2016
Q3 		$468 Sell
38,936
-7,170
-16% -$97.1K ﹤0.01% 2876
2016
Q2 		$507K Buy
46,106
+34,067
+283% +$417K ﹤0.01% 2849
2016
Q1 		$105K Hold
12,039
– – ﹤0.01% 3030
2015
Q4 		$264K Buy
+12,039
New +$277K ﹤0.01% 3036

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

TIAA CREF Investment Management's VYGR Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Voyager Therapeutics (VYGR) stake by 43% in Q1 2019, buying an estimated $320K and bringing the position to 81,968 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2118.

TIAA CREF Investment Management first reported a position in VYGR in Q4 2015 and has held it in 14 quarters since. The position peaked at $1.59M in Q2 2018. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

  • TIAA CREF Investment Management held 81,968 shares of Voyager Therapeutics worth $1.57M as of Q1 2019.
  • TIAA CREF Investment Management bought 24,543 Voyager Therapeutics shares in Q1 2019, an estimated $320K.
  • Voyager Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2118 holding.
  • TIAA CREF Investment Management first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 14 quarters since.
  • TIAA CREF Investment Management's Voyager Therapeutics position peaked at $1.59M in Q2 2018.
  • 111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.